Palbenz 125 mg is a targeted therapy containing the active constituent palbociclib. It belongs to the group of anticancer medications known as cyclin-dependent kinase inhibitors. It is used in treating hormone receptor-positive, human epidermal growth factor 2 negative advanced or metastatic (has spread to other parts of the body) breast cancer. Cancer is a condition in which cells multiply in an uncontrolled and abnormal manner. It is given in combination with certain other anticancer medications. 

The common side effects that are likely to associate with Palbenz 125 mg are nausea, vomiting, diarrhea, tiredness, hair loss, dry skin, rash, infections, nose bleed, decreased appetite, low blood cell counts, swelling of lips and mouth, changes in taste, dry eye, blurred vision, and increased tearing. Inform your doctor if these side effects disturb or persist in you.  

Inform your healthcare provider if you are allergic to Palbenz 125 mg and its ingredients. Before taking this medicine, it is vital to inform your doctor if you have any signs of infections (fever, chills, or sore throat), liver disorders, kidney disorders, or intolerance to some sugars. Consult your physician immediately if you experience symptoms such as dry cough, chest pain, or difficulty breathing, as it could indicate lung inflammation. Make sure you inform your physician of all the medicines, including supplements and herbal medicines. You are taking before you start treatment with this medication. Use effective birth control during the treatment and at least three weeks after the last dose. It is not recommended for adolescents and children under 18 years of age. Palbenz 125mg Capsule price varies by retailer and location. Palbenz Capsule alternatives include Ciclib, Bdpalbo, Palnat, Pabreca, Kixta, Piciclib, PALENO, and Palborest, along with other CDK4/6 inhibitors like Abemaciclib (Verzenio) and Ribociclib (Kisqali).

Palbenz 125mg Capsule uses: 

• Treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer.

Palbenz 125 mg works by blocking the protein called cyclin-dependent kinases 4 and 6, which are vital for the division and growth of cells. By blocking these proteins, this medication slows the growth and prevents the cancer cells from spreading. 

Inform your doctor about all medications including prescribed, over-the-counter, nutritional or vitamin supplements and herbal products that you are taking or have taken before the treatment. Concurrent use of Palbenz 125mg with CYP3A4 inhibitors such as fentanyl has reported increased fentanyl toxicity. certain medications may interact with the effectiveness of this drug. 

• Keep Palbenz 125 mg out of sight and reach of children.
• Store at 20°C to 25°C.

Take Palbenz 125 mg exactly as prescribed by your doctor. Take this medication once a day at the same time with food. Swallow this capsule as a whole with a glass of water. Avoid crushing, breaking, or chewing the capsule. 

Palbenz 125mg Capsule side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.

Serious:

• Blood disorder (fever, chills, shortness of breath, weakness, bleeding, or bruising)
• Lung inflammation (chest pain, dry cough, or difficulty breathing)

Common:

• Tiredness
• Hair loss
• Dry skin, rash
• Infections
• Low blood cell counts
• Decreased of appetite
• Nausea, vomiting
• Diarrhea
• Swelling of lips and mouth
• Changes in taste
• Nose bleed
• Dry eye, blurred vision, increased tearing

• Avoid grapefruit, grapefruit juice, and St. John’s wort while taking Palbenz 125 mg.

• Use effective contraception during treatment, and continue for 3 weeks after the last dose (females) or 14 weeks (males).

• This medicine may reduce fertility, so discuss any concerns with your doctor.

• Regular blood tests may be recommended to monitor the effect of Palbenz 125 mg on your blood cells.

1. Pfizer Limited, Electronic medicines compendium (emc), [Revised on June 2021] [ Accessed on 26 Nov 2022], https://www.medicines.org.uk/emc/files/pil.4449.pdf
2. Pfizer Labs, US Food and Drug Administration, [Revised on March 2017] [ Accessed on 26 Nov 2022], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf
3. Neha S Mangini et al; Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer; The Annals of Pharmacotherapy; Published on Nov 2015; Accessed on 26/11/2022; https://pubmed.ncbi.nlm.nih.gov/26324355/
4. Palbace; Pfizer; Revised on Oct 2021; Accessed on 26/11/2022; https://labeling.pfizer.com/ShowLabeling.aspx?id=14029